Autor: |
Ceder S; Department of Oncology-Pathology, Karolinska Institutet, BioClinicum J6, Stockholm, Sweden., Eriksson SE; Department of Oncology-Pathology, Karolinska Institutet, BioClinicum J6, Stockholm, Sweden., Liang YY; Department of Oncology-Pathology, Karolinska Institutet, BioClinicum J6, Stockholm, Sweden.; Institute of Molecular and Cellular Biology, A*STAR, Singapore, Singapore., Cheteh EH; Department of Oncology-Pathology, Karolinska Institutet, BioClinicum J6, Stockholm, Sweden., Zhang SM; Science For Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden., Fujihara KM; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia., Bianchi J; Department of Oncology-Pathology, Karolinska Institutet, BioClinicum J6, Stockholm, Sweden., Bykov VJN; Department of Oncology-Pathology, Karolinska Institutet, BioClinicum J6, Stockholm, Sweden., Abrahmsen L; Aprea Therapeutics AB, Solna, Sweden., Clemons NJ; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia., Nordlund P; Department of Oncology-Pathology, Karolinska Institutet, BioClinicum J6, Stockholm, Sweden.; Institute of Molecular and Cellular Biology, A*STAR, Singapore, Singapore., Rudd SG; Science For Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden., Wiman KG; Department of Oncology-Pathology, Karolinska Institutet, BioClinicum J6, Stockholm, Sweden. Klas.Wiman@ki.se. |